`
`Lucentis PFS (RFB002)
`
`TRD SubTeam meeting
`
`Minutes
`
`Business Use Only
`
`Meeting Date: Oct. 1. 2012
`Meeting Notes Date: 24.10.2012
`Author:
`Room: WSJ-340.3.09
`Dial-in:
`
`D
`
`r£Jerences.msg
`
`Team Members : (✓ = Present, *= part-time)
`
`Team Members:(✓ = Present,*= part-time)
`
`✓
`✓
`
`✓
`
`Executive Summar
`
`Topic/Situation: Project update
`
`Project update
`
`Discussion
`
`tead:
`
`Pre-reads
`None
`
`TR D Subteam Meeting Minutes: Date of Meeting: October 15, 201 2
`
`1 of 6
`
`CONTAINS CONFIDENTIAL BUSINESS INFORMATION, SUBJECT TO PROTECTIVE ORDER
`Novartis Exhibit 2086.001
`Regeneron v. Novartis, IPR2021-00816
`
`
`
`Achievements
`n.a.
`Issues
`What
`n.a.
`Actions
`What
`n.a.
`
`Topic/Situation
`
`Open
`
`Who
`
`Closed
`
`When
`
`-
`
`TR D Subteam Meeting Minutes: Date of Meeting: October 15, 2012
`
`2 of 6
`
`CONTAINS CONFIDENTIAL BUSINESS INFORMATION, SUBJECT TO PROTECTIVE ORDER
`Novartis Exhibit 2086.002
`Regeneron v. Novartis, IPR2021-00816
`
`
`
`Achievements
`
`Issues
`What
`n.a.
`Actions
`
`Topic/Situation
`
`Discussion
`
`Closed
`
`0 en
`
`.Who -
`
`TR D Subteam Meeting Minutes: Date of Meeting: October 15, 2012
`
`3 of 6
`
`CONTAINS CONFIDENTIAL BUSINESS INFORMATION, SUBJECT TO PROTECTIVE ORDER
`Novartis Exhibit 2086.003
`Regeneron v. Novartis, IPR2021-00816
`
`
`
`Achievements
`
`Issues
`What .
`
`Topic/Situc,tion:
`
`Closed
`
`Open
`
`Who
`
`Achievements.
`
`TR D Subteam Meeting Minutes: Date of Meeting: October 15, 2012
`
`4 of 6
`
`CONTAINS CONFIDENTIAL BUSI NESS INFORMAT ION, SUBJECT TO PROTECTIVE ORDER
`Novartis Exhibit 2086.004
`Regeneron v. Novartis, IPR2021-00816
`
`
`
`Issues
`What
`n.a.
`Actions
`What
`
`Consolidated Action Plan
`
`Closed
`
`When
`
`0 n
`
`Who
`
`-
`
`TR D Subteam Meeting Minutes: Date of Meeting: October 15, 2012
`
`5 of 6
`
`CONTAINS CONFIDENTIAL BUSINESS INFORMATION, SUBJECT TO PROTECTIVE ORDER
`Novartis Exhibit 2086.005
`Regeneron v. Novartis, IPR2021-00816
`
`
`
`TR D Subteam Meeting Minutes: Date of Meeting: October 15, 2012
`
`6 of 6
`
`CONTAINS CONFIDENTIAL BUSINESS INFORMATION, SUBJECT TO PROTECTIVE ORDER
`Novartis Exhibit 2086.006
`Regeneron v. Novartis, IPR2021-00816
`
`